Research Antibodies and Reagents Sales

Research Antibodies and Reagents Sales Market Outlook

The global Research Antibodies and Reagents market is projected to reach USD 45 billion by 2035, growing at a CAGR of approximately 7.5% from 2025 to 2035. This expansion is significantly driven by the increasing prevalence of chronic diseases necessitating advanced research and development in biopharmaceuticals, coupled with rising investments in life sciences research. Furthermore, the surge in academic and commercial research activities surrounding drug discovery is anticipated to drive market growth. The rising demand for personalized medicine and the growing adoption of advanced technologies in laboratories is also propelling the market forward. Additionally, an increase in public and private funding for research initiatives is fostering an environment conducive to innovation and growth in this sector.

Growth Factor of the Market

Several factors are fueling the growth of the Research Antibodies and Reagents market, with the foremost being the rapid technological advancements in biotechnological research. Innovations such as next-generation sequencing, CRISPR gene editing, and high-throughput screening are enhancing research capabilities, thus increasing the demand for highly specific and effective antibodies and reagents. Moreover, the increased incidences of cancer, autoimmune diseases, and infectious diseases are driving up the need for precise diagnostic tools, which rely heavily on antibodies for accurate detection and analysis. The rise in collaborations between academic institutions and biotechnology companies has also been pivotal, as such partnerships often lead to breakthroughs that require extensive use of antibodies in research. Lastly, the growing emphasis on personalized medicine is compelling researchers to seek out high-quality reagents that can be tailored to specific patient needs.

Key Highlights of the Market

• Rapid growth projected due to technological advancements in research methodologies.
• Increased focus on personalized medicine is driving demand for custom antibodies.
• Significant collaborations between academic and commercial entities to boost innovation.
• Rising incidences of chronic diseases necessitating the development of effective diagnostic tools.
• Expanding market presence in emerging economies through increased research funding.

By Product Type

Primary Antibodies:

Primary antibodies are essential tools in various research applications, as they bind specifically to target antigens. Their role is crucial in techniques such as Western blotting, immunohistochemistry, and flow cytometry, making them a significant segment of the antibodies market. The demand for primary antibodies is driven by their key role in aiding researchers to identify and quantify proteins of interest in different biological samples. The growing research in proteomics and genomics has expanded the need for highly specific primary antibodies, leading to continuous innovations in this segment including the development of monoclonal and polyclonal variants. As research becomes increasingly complex, the market for primary antibodies is expected to witness robust growth, with an emphasis on quality and specificity.

Secondary Antibodies:

Secondary antibodies play a significant supporting role in research applications, as they are designed to bind to primary antibodies. This functionality is critical in amplifying the signal during detection procedures, enhancing the sensitivity and specificity of various assays. The increasing application of secondary antibodies in immunological assays and diagnostics is propelling this segment's growth. Furthermore, advancements in labeling techniques, such as fluorescent and enzyme-conjugated secondary antibodies, have improved their utility in various applications, including imaging and flow cytometry. As more researchers and laboratories adopt these enhanced detection methods, the secondary antibodies market is projected to grow significantly, driven by demand for high-performance reagents.

Antibody Kits:

Antibody kits are comprehensive solutions that provide researchers with everything they need to conduct specific experiments, including primary and secondary antibodies, buffers, and protocols. These kits save time and ensure reproducibility in experiments, making them increasingly popular among laboratories. The convenience of ready-to-use kits has contributed to their market growth, especially in resource-limited settings where researchers may lack access to advanced facilities or expertise. Additionally, as the trend towards standardized and validated workflows continues to gain traction in laboratories, the demand for antibody kits is expected to rise. Manufacturers are also focusing on creating kits tailored for specific applications, further driving the segment's expansion.

Reagents:

Reagents are essential for various biochemical assays, playing a vital role in supporting the overall antibody testing process. The market for reagents is experiencing growth due to the ongoing development and optimization of laboratory techniques that rely on specific reagents to facilitate reactions and analyses. With the increasing number of research projects in biotechnology, molecular biology, and diagnostics, the demand for high-quality reagents is on the rise. The market is also witnessing a trend towards the development of more sophisticated reagents, such as those used in multiplex assays and high-throughput screening, which further enhances research capabilities and drives growth in this segment.

Custom Antibodies:

Custom antibodies, designed specifically for unique research needs, are gaining popularity as researchers seek solutions tailored to their specific experiments. This segment is fueled by the increasing complexity of biological research, which often requires highly specialized antibodies that cannot be found in off-the-shelf products. Custom antibody services provide researchers with the flexibility to develop antibodies against specific antigens, enabling more precise results. Additionally, advancements in technology have made the production of custom antibodies more efficient and cost-effective, further driving their adoption in research settings. As the trend towards personalized medicine continues, the demand for custom antibodies is likely to increase significantly.

By Application

Protein Research:

Protein research is a fundamental area of study in biology and biochemistry, focusing on understanding the structure, function, and interactions of proteins in various biological systems. Antibodies play a crucial role in protein research, as they are used to detect and analyze proteins in complex samples. The growth of this application is largely driven by advancements in proteomics and the need for more detailed analysis of proteins in disease contexts. As researchers delve deeper into the intricacies of cellular mechanisms and signaling pathways, the demand for high-quality antibodies and reagents specifically tailored for protein research is expected to grow.

Drug Discovery & Development:

Drug discovery and development is a critical component of the pharmaceutical industry, where high-quality antibodies are essential for various phases of research, including target identification, validation, and biomarker discovery. As the need for new therapeutics rises, driven by increasing disease prevalence and challenges in healthcare, the demand for antibodies that can assist in drug discovery processes is also growing. The trend towards biologics and monoclonal antibody therapies has further emphasized the need for robust antibody-based assays in drug development pipelines. As a result, the market for antibodies in this application is experiencing significant growth, with researchers seeking efficient, reliable, and specific tools to expedite their workflows.

Immunology:

Immunology is a branch of biomedical science focused on the immune system and its responses to pathogens and diseases. The increasing prevalence of autoimmune diseases and infectious diseases has heightened the importance of immunological research, which directly translates to a growing demand for research antibodies. Antibodies are pivotal for understanding immune mechanisms, developing vaccines, and conducting diagnostics. The rise in funding for immunological studies and advancements in antibody production techniques are key drivers of growth in this segment. As ongoing research aims to unlock new immunological insights, the demand for high-quality antibodies tailored for immunological applications is expected to surge.

Neuroscience:

Neuroscience research has gained significant momentum in recent years, with a focus on understanding complex neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Antibodies are a vital tool in neuroscience, allowing researchers to study neuronal structures, synaptic functions, and neuroinflammation. With funding and interest in neurological research on the rise, the demand for specialized antibodies that can target neural proteins and pathways is increasing. This growth is further fueled by advancements in methods such as immunohistochemistry and live-cell imaging, which rely heavily on the availability of effective antibodies. As the field continues to evolve, the market for antibodies in neuroscience is expected to grow robustly.

Oncology:

Oncology research has become one of the fastest-growing segments within the life sciences research sector, primarily due to the increasing incidence of cancer worldwide. Antibodies play a crucial role in cancer research and therapy, including the development of monoclonal antibody treatments and diagnostic assays for tumor markers. The growing emphasis on personalized cancer therapies, which require specific antibodies for patient stratification, is driving the demand for research antibodies in this field. Moreover, advancements in targeted therapies and immunotherapy are further fueling growth, as researchers increasingly rely on antibodies to develop effective treatment strategies. As more breakthroughs are made in cancer research, the market for antibodies in oncology is likely to experience continuous expansion.

By Distribution Channel

Direct Sales:

Direct sales remain a prominent distribution channel in the Research Antibodies and Reagents market, enabling manufacturers to engage directly with their customers. This approach allows for greater control over pricing, customer service, and product availability, which can enhance customer satisfaction and loyalty. Companies that utilize direct sales often employ dedicated sales teams to build relationships with researchers and laboratories, providing tailored solutions to meet specific needs. This personalized service can lead to increased sales volumes and a better understanding of market trends and customer preferences. As the market continues to evolve, direct sales are expected to play a crucial role in reaching a diverse clientele.

Distributor Sales:

Distributor sales are another vital channel in the Research Antibodies and Reagents market, representing a network of intermediaries that facilitate the distribution of products to various end-users. Distributors often have established relationships with research institutions and laboratories, enabling them to effectively promote and sell antibodies and reagents. This channel is particularly beneficial for small and medium-sized enterprises (SMEs) that may lack the resources to manage direct sales operations. As the demand for antibodies continues to grow, distributor sales are expected to expand, providing manufacturers with a broader reach and access to new markets. The convenience of purchasing through established distributors can also drive customer preference for this channel.

By Antibody Type

Monoclonal Antibodies:

Monoclonal antibodies are a cornerstone of modern biomedical research and therapy, characterized by their ability to bind to specific antigens with high affinity and specificity. This uniqueness makes them invaluable in various applications, including diagnostic assays, therapeutic drug development, and academic research. The growing prevalence of chronic diseases and the need for effective treatments have significantly fueled the demand for monoclonal antibodies. As researchers continue to explore novel therapeutic targets and develop new applications, the market for monoclonal antibodies is expected to experience robust growth. Advances in production technologies and strategies to enhance efficacy and reduce immunogenicity are also driving innovation in this segment.

Polyclonal Antibodies:

Polyclonal antibodies, derived from multiple B-cell lineages, provide a diverse set of recognition sites for various epitopes on an antigen. This characteristic makes polyclonal antibodies particularly useful in applications where multiple binding sites are advantageous, such as in assays that require higher sensitivity and tolerance to antigen variability. The market for polyclonal antibodies is experiencing growth as researchers continue to seek reagents that can provide robust and reproducible results across diverse experimental conditions. Additionally, the accessibility and cost-effectiveness of polyclonal antibody production compared to monoclonal antibodies is driving their adoption in academic and commercial settings. As research demands evolve, the significance of polyclonal antibodies in various fields remains evident.

Recombinant Antibodies:

Recombinant antibodies are engineered to enhance specificity and efficacy, making them a cutting-edge choice in research and therapeutic applications. Their production involves sophisticated technologies such as phage display and hybridoma systems, which allow for the creation of highly specific antibodies against challenging targets. The increasing complexity of biological research and the need for more precise tools are leading to a growing demand for recombinant antibodies. Furthermore, as researchers increasingly focus on personalized medicine and targeted therapies, the role of recombinant antibodies in diagnostics and therapeutics is anticipated to expand significantly. Innovations in the development and validation of recombinant antibodies continue to propel this segment forward, solidifying its importance in the market.

Phage Display Antibodies:

Phage display technology allows for the rapid identification and selection of antibodies that bind to specific targets, making it a valuable tool in both research and therapeutic development. Antibodies generated through phage display exhibit high specificity and diversity, which is particularly advantageous in identifying unique biomarkers for various diseases. As the demand for high-throughput screening technologies increases, the phage display antibodies market is expected to see significant growth. Researchers are increasingly leveraging this technology to discover and develop novel therapeutic antibodies, further driving market expansion. With advancements in phage display methodologies, the efficiency and effectiveness of antibody discovery are likely to improve, reinforcing the relevance of this segment in the broader antibodies market.

Chimeric Antibodies:

Chimeric antibodies, which combine elements from different antibody sources, are an innovative approach to overcoming the limitations of traditional antibody therapies. This unique design allows for enhanced binding affinities and reduced immunogenicity, making them particularly suitable for therapeutic applications. The surge in interest for innovative therapies in oncology and autoimmune diseases is propelling the demand for chimeric antibodies. As researchers look for effective solutions that minimize adverse reactions while maximizing therapeutic efficacy, chimeric antibodies are gaining prominence. The continuous advancements in antibody engineering technologies are likely to lead to the development of more specialized chimeric antibodies, further expanding this segment's growth potential.

By Region

The North American Research Antibodies and Reagents market holds a significant share, estimated at around USD 16 billion in 2025, supported by advanced research infrastructure and high levels of funding for biomedical research. The presence of major biotechnology and pharmaceutical companies in this region accelerates innovation and drives demand for research antibodies and reagents. Furthermore, increasing investments in life sciences research and a robust network of academic institutions contribute to the continual growth of this market segment. With a projected CAGR of 7% from 2025 to 2035, North America is expected to maintain its leadership in the global market.

In Europe, the Research Antibodies and Reagents market is anticipated to reach approximately USD 12 billion by 2035, fueled by an upsurge in public and private research funding. The emphasis on collaborative research initiatives and the establishment of research consortia are pivotal in driving growth across countries in this region. Additionally, the expansion of biotechnology sectors in Eastern European countries is further contributing to regional market growth. As researchers increasingly adopt advanced technologies, the demand for high-quality antibodies and reagents will continue to rise, reinforcing Europe’s significant presence in this market.

Opportunities

The Research Antibodies and Reagents market is poised for considerable opportunities, primarily driven by the ongoing advancements in biotechnology and personalized medicine. As researchers continue to explore complex biological processes, the demand for high-quality, specific antibodies is surging. Companies that can innovate and provide reliable, specialized antibodies will likely find extensive growth potential in areas such as immunotherapy, gene editing, and precision diagnostics. Furthermore, the increasing integration of artificial intelligence and machine learning into research processes presents an exciting opportunity for manufacturers to develop smarter antibody discovery and validation methodologies. By harnessing these technological advancements, companies can enhance their product offerings and improve the efficiency of research workflows across various disciplines.

Emerging markets also present significant opportunities for growth in the Research Antibodies and Reagents sector. Countries in Asia Pacific and Latin America are witnessing increased investments in life sciences research, driven by both government initiatives and private sector funding. As research institutions expand and modernize, the demand for high-quality antibodies and reagents will naturally increase. Companies that establish a presence in these regions can capitalize on the growing research activities and the rising need for effective research tools. By tailoring products and services to meet the specific needs of these markets, businesses can tap into a burgeoning customer base eager for innovative solutions.

Threats

Despite the robust growth prospects in the Research Antibodies and Reagents market, several threats could pose challenges to industry players. One of the most significant threats is the increasing competition from alternative approaches and technologies that may replace traditional antibody applications. For instance, advancements in synthetic biology and protein engineering could lead to the development of novel reagents that provide similar or improved functionalities without relying on traditional antibodies. As these technologies continue to evolve, established manufacturers may face pressure to adapt quickly to maintain their market positions. Additionally, the prevalence of counterfeit antibodies poses a threat to the integrity of research outcomes, leading to increased scrutiny and demand for quality assurance from both researchers and funding bodies.

Moreover, regulatory challenges and compliance requirements can act as significant restraining factors within the Research Antibodies and Reagents market. The stringent regulations governing the production, testing, and distribution of research antibodies can increase operational costs and complicate market entry, particularly for small and medium-sized enterprises. As global regulatory standards continue to shift, companies will need to invest in ensuring compliance with various guidelines, which may strain resources and slow down innovation. Addressing these challenges will be crucial for industry players aiming to sustain growth and maintain a competitive edge in an evolving market landscape.

Competitor Outlook

• AbbVie Inc.
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• SAB Biotherapeutics
• Bio-Rad Laboratories, Inc.
• Genscript Biotech Corporation
• Cell Signaling Technology, Inc.
• Abcam plc
• Santa Cruz Biotechnology, Inc.
• Lonza Group AG
• Genentech, Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.

The competitive landscape of the Research Antibodies and Reagents market is characterized by a variety of key players, each vying for market share through innovation, quality enhancements, and strategic partnerships. Companies like Thermo Fisher Scientific and Roche stand out due to their extensive product portfolios and established reputations in the field. They continually invest in research and development to introduce cutting-edge products that cater to evolving research needs. Additionally, the presence of specialized companies like Abcam and Bio-Rad Laboratories reflects the market's diverse landscape, where firms focus on niche applications to differentiate themselves from larger competitors. This competition fosters an environment of innovation, ultimately benefiting researchers and advancing the field.

Major companies such as AbbVie and Merck KGaA leverage their substantial resources to drive growth through acquisitions and collaborations. These strategies enable them to enhance their product offerings, expand their customer base, and enter new markets. For instance, AbbVie's recent acquisition of a smaller biotech firm has allowed it to gain access to novel antibody technologies, expanding its capabilities in therapeutic development. Similarly, companies like Genscript Biotech and Cell Signaling Technology are focusing on enhancing their technical capabilities, offering customized services that cater to specific research requirements. Their commitment to quality and precision positions them well in an increasingly competitive market.

Additionally, regulatory compliance and quality assurance are pivotal for companies operating in this space. Organizations such as Lonza and Genentech prioritize adherence to regulatory standards in their manufacturing processes, ensuring the reliability and efficacy of their antibodies and reagents. This commitment to quality not only protects researchers but also enhances brand loyalty and trust. Moreover, the competitive landscape is evolving as emerging players enter the market, driven by advancements in technology and an increasing focus on personalized medicine. Overall, the Research Antibodies and Reagents market presents a dynamic and competitive environment that continues to evolve in response to the needs of researchers and advancements in biotechnology.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Abcam plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Lonza Group AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genentech, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 SAB Biotherapeutics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bio-Rad Laboratories, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Genscript Biotech Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Santa Cruz Biotechnology, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Cell Signaling Technology, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Research Antibodies and Reagents Sales Market, By Application
    • 6.1.1 Protein Research
    • 6.1.2 Drug Discovery & Development
    • 6.1.3 Immunology
    • 6.1.4 Neuroscience
    • 6.1.5 Oncology
  • 6.2 Research Antibodies and Reagents Sales Market, By Product Type
    • 6.2.1 Primary Antibodies
    • 6.2.2 Secondary Antibodies
    • 6.2.3 Antibody Kits
    • 6.2.4 Reagents
    • 6.2.5 Custom Antibodies
  • 6.3 Research Antibodies and Reagents Sales Market, By Antibody Type
    • 6.3.1 Monoclonal Antibodies
    • 6.3.2 Polyclonal Antibodies
    • 6.3.3 Recombinant Antibodies
    • 6.3.4 Phage Display Antibodies
    • 6.3.5 Chimeric Antibodies
  • 6.4 Research Antibodies and Reagents Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Research Antibodies and Reagents Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Research Antibodies and Reagents Sales market is categorized based on

By Product Type

• Primary Antibodies
• Secondary Antibodies
• Antibody Kits
• Reagents
• Custom Antibodies

By Application

• Protein Research
• Drug Discovery & Development
• Immunology
• Neuroscience
• Oncology

By Distribution Channel

• Direct Sales
• Distributor Sales

By Antibody Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Phage Display Antibodies
• Chimeric Antibodies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• SAB Biotherapeutics
• Bio-Rad Laboratories, Inc.
• Genscript Biotech Corporation
• Cell Signaling Technology, Inc.
• Abcam plc
• Santa Cruz Biotechnology, Inc.
• Lonza Group AG
• Genentech, Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.